Literature DB >> 8385283

Acute reversible renal failure with macroscopic haematuria in IgA nephropathy.

C Delclaux1, C Jacquot, P Callard, D Kleinknecht.   

Abstract

Macroscopic haematuria is common in IgA nephropathy, but its significance and influence on prognosis remains uncertain. We compared the clinical and pathological features of 11 adult patients with primary IgA nephropathy who had had a renal biopsy during or shortly after a bleeding episode. Six patients developed transient acute renal failure (ARF) (group 1) and five did not (group 2). Patients of group 1 had a higher percentage of tubular red-blood-cell (RBC) casts (P < 0.05) and of glomerular crescents (P < 0.001). However, crescents were focal and involved less than 50% of glomeruli. Acute tubular necrosis was only present in patients of group 1, and ARF was attributed to the acute tubular changes rather than to the glomerular lesions. Despite a prolonged duration of ARF (mean: 38 days), further outcome did not differ in patients of both groups. We suggest that acute tubular damage and/or tubular obstruction by RBC casts should be considered in any patient who develops ARF soon after a haematuric episode.

Entities:  

Mesh:

Year:  1993        PMID: 8385283

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

1.  Atypical triad of IgA nephropathy: reversible acute kidney injury, gross hematuria, and severe bilateral flank pain.

Authors:  Susan Kim; Warren Chang
Journal:  CEN Case Rep       Date:  2013-12-17

2.  The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: crescents and timing of renal biopsy.

Authors:  Rosanna Coppo; Jean-Claude Davin
Journal:  Pediatr Nephrol       Date:  2014-10-16       Impact factor: 3.714

3.  Comparison of prominent glomerular injury and prominent tubular injury in immunoglobulin A nephropathy.

Authors:  Yao-Ko Wen
Journal:  Int Urol Nephrol       Date:  2009-12-18       Impact factor: 2.370

4.  Dabigatran causing severe acute kidney injury in a patient with liver cirrhosis.

Authors:  Xin Li; Chi Yuen Cheung
Journal:  CEN Case Rep       Date:  2019-01-18

Review 5.  Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity.

Authors:  Rigas G Kalaitzidis; Anila Duni; Georgios Liapis; Olga Balafa; Sofia Xiromeriti; Paulos Karolos Rapsomanikis; Moses S Elisaf
Journal:  Int Urol Nephrol       Date:  2017-02-04       Impact factor: 2.370

6.  Clinical features and outcomes of IgA nephropathy with nephrotic syndrome.

Authors:  Jwa-Kyung Kim; Jeong Ho Kim; Sang Choel Lee; Ea Wha Kang; Tae Ik Chang; Sung Jin Moon; Soo Young Yoon; Tae-Hyun Yoo; Shin-Wook Kang; Kyu Hun Choi; Dae Suk Han; Jeong Hae Kie; Beom Jin Lim; Hyeon Joo Jeong; Seung Hyeok Han
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

7.  Nephrotic syndrome is a rare manifestation of IGA nephropathy.

Authors:  Ahmad A Alshomar
Journal:  Int J Health Sci (Qassim)       Date:  2016-07

Review 8.  An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy.

Authors:  Ron Hogg
Journal:  Pediatr Nephrol       Date:  2021-05-13       Impact factor: 3.714

9.  Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission.

Authors:  Zhaohui Ni; Yanhong Yuan; Qin Wang; Liou Cao; Xiajing Che; Minfang Zhang; Yuanyuan Xie; Chaojun Qi; Shan Mou
Journal:  J Transl Med       Date:  2014-07-10       Impact factor: 5.531

10.  Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort.

Authors:  Suceena Alexander; Santosh Varughese; Rajanbabu Franklin; Sanjeet Roy; Grace Rebekah; Vinoi George David; Anjali Mohapatra; Anna T Valson; Shibu Jacob; Pradeep Mathew Koshy; Gautham Rajan; Mohamed R Daha; John Feehally; Jonathan Barratt; George T John
Journal:  Kidney Int Rep       Date:  2020-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.